AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00078338
Drug: Copaxone®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be administered with Copaxone® (Glatiramer acetate) as subcutaneous (SC) injection at a dose of 20 milligram (mg) once daily (qd).
Trial: NCT01245140
Drug: alitretinoin
RxNorm normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: to receive verum (20 patients)
Trial: NCT01245140
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: to receive placebo (10 patients)
Trial: NCT00005977
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00005977
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02340520
Drug: Theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT00005977
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00005977
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01483144
Drug: Sulindac 150 MG
RxNorm normalized name: sulindac 150 MG
DrugBank: Sulindac (DB00605)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulindac \[one tablet orally once a day\]
Trial: NCT01483144
Drug: Sulindac placebo
RxNorm normalized name: Sulindac
DrugBank: Sulindac (DB00605)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulindac placebo \[one tablet orally once a day\]
Trial: NCT03818126
Drug: del Nido cardioplegia
RxNorm normalized name: Del Nido Cardioplegia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The del Nido components are: Plasma-Lyte A (1000ml), Mannitol 20% (16.3ml), MgSO4 50% (4ml) , NaHCO3 8.4% (13ml) , KCl 2mEq/mL (13ml), Lidocaine 1% (13ml). This solution is mixed with autologous patient blood from the cardiopulmonary circuit in a 4:1 ratio (crystalloid:blood).~The dosage is 20ml/kg. The target administration pressure is 100-200mmHg and the target administration flow is 200-300ml/min. The solution temperature is 4 degrees Celsius. Additional dose of the cardioplegia is given only if the cross-clamp time exceeds 90 minutes. Due to high volume given in a single delivery, 40 milligrams of furosemide are injected into cardiopulmonary circuit.
Trial: NCT03818126
Drug: cold blood cardioplegia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The cold blood cardioplegia components are: Plasma-Lyte A (435ml), Mannitol 15% (20ml), NaHCO3 8.4% (20ml), KCl 2mEq/mL (25ml). The solution is mixed with autologous patient blood from the cardiopulmonary circuit in a 1:4 ratio (crystalloid:blood).~The initial dose is 15ml/kg and a dose of 5ml/kg is added every 20-30 minutes or whenever cardiac activity is observed. The target administration pressure is 100-200mmHg and the target administration flow is 200-300ml/min. The solution temperature is 4 degrees Celsius.
Trial: NCT02883595
Drug: thymosin alpha 1
RxNorm normalized name: Thymosin alpha 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injections of 1.6 mg thymosin alpha 1 twice per day for seven days, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.
Trial: NCT02530710
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00421655
Drug: Grazax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets 75,000 SQT and matching placebo. One tablet daily.
Trial: NCT01810939
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00960362
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 0 mg/kg administered intravenously (in the vein) cohort 1-6.
Trial: NCT00484822
Drug: Heparina Cálcica
RxNorm normalized name: Heparina
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10.000 UI/día.
Trial: NCT03499626
Drug: ASLAN001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose at 300mg BD Dose level +1: 400mg BD (which is the target dose for this study)~Dose reduction of ASLAN001 in event of adverse events grade 2 and above:~Dose level -1: 200mg BD Dose level -2: 100mg BD
Trial: NCT00844337
Drug: Penicillin & gentamicin x 2 d + Amoxicillin X 5 d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable penicillin and gentamicin once daily for two days followed by oral amoxicillin twice daily for five days. The dose for penicillin is 40,000 - 50,000 U/kg/24 hours, the dose for gentamicin is 4 - 5 mg/kg/24 hours, and the dose for amoxicillin is 90-115 mg/kg/day.
Trial: NCT02204293
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo administered subcutaneously.
Trial: NCT00196469
Drug: heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00193479
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide
Trial: NCT02932930
Drug: 0.9% normal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0,2ml/kg of 0.9% normal saline
Trial: NCT00731133
Drug: Disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 mg/day
Trial: NCT00945672
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo administered every 90 days or monthly to match experimental treatment arms.
Trial: NCT00476073
Drug: FLUTIFORM® (Formoterol fumarate / Fluticasone propionate)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00913549
Drug: Tavist Tablets, 2.68 mg (Sandoz Pharmaceutical Corp.)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00786474
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution, dosage determined by weight, self-administered by patient twice a day
Trial: NCT01395004
Drug: GSK2110183
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2110183 was orally administered at 125 mg once daily.
Trial: NCT03994731
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral MTX 15 mg weekly
Trial: NCT02532322
Drug: IV acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV acetaminophen 15 mg/kg (1.5 mL/kg) IV loading dose prior to incision, followed by a 15 mg/kg (1.5 mL/kg) dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)
Trial: NCT03994731
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo for MTX
Trial: NCT03994731
Drug: gout flare prophylaxis regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior to beginning the Pegloticase + IMM Period, participants must have been taking at least 1 protocol-standard gout flare prophylaxis regimen (i.e. colchicine and/or nonsteroidal anti-inflammatory drugs and/or low-dose prednisone ≤ 10 mg/day) for ≥ 1 week before the first dose of pegloticase and to continue flare prophylaxis per American College of Rheumatology guidelines \[Khanna D et al. 2012\] for the greater of 1) 6 months, 2) 3 months after achieving target serum urate (sUA \< 6 mg/dL) for participants with no tophi detected on physical exam, or 3) 6 months after achieving target serum urate (sUA \< 5 mg/dL) for participants with one or more tophi detected on initial physical exam that then resolved.
Trial: NCT03994731
Drug: acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For IR prophylaxis, acetaminophen (1000 mg orally) taken the morning of each infusion.
Trial: NCT02532322
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline 1.5 mL/kg IV loading dose prior to incision, followed by a 1.5 mL/kg dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)
Trial: NCT04370015
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: • Health care workers at high risk of contracting SARS-CoV-2 randomized to this arm will be treated with placebo twice a day (four tablets) on day 1 followed by 2 tablets once a week for 11weeks.
Trial: NCT01199068
Drug: CS-7017
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-7017 from 0.25 mg to 0.50 mg twice daily
Trial: NCT05770960
Drug: codeine phosphate
RxNorm normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Codeine after waking up from the Midazolam administration during the colonoscopy.
Trial: NCT01277692
Drug: GSK2336805 10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose once daily
Trial: NCT01277692
Drug: GSK2336805 30mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose once daily
Trial: NCT01277692
Drug: GSK2236805 100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose once daily
Trial: NCT01277692
Drug: GSK2236805 200mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose once daily
Trial: NCT01277692
Drug: GSK2236805 10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: repeat dose once daily for 7 days
Trial: NCT01277692
Drug: GSK2236805 dose to be determined up to 100mg
RxNorm normalized name: Born To Be Mild
FDA approved: no
EMA approved: no
PMDA approved: no
Description: repeat dose once daily for 7 days
Trial: NCT01277692
Drug: GSK2236805 5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose in HCV infected patients
Trial: NCT01277692
Drug: GSK2236805 30mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose in HCV infected patients
Trial: NCT01277692
Drug: GSK2236805 100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose in HCV infected patients
Trial: NCT00003704
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00424034
Drug: GSK1325760A
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00374036
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan
Trial: NCT04727138
Drug: EXS21546 Powder for Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EXS21546 Powder for Oral Suspension
Trial: NCT04727138
Drug: EXS21546 Granule in Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EXS21546 Granule in Capsule
Trial: NCT02514681
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03471858
Drug: Prostaglandins
RxNorm normalized name: PROSTAGLANDINS
DrugBank: Prostaglandin G2 (DB03866)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostin will be used in the control arm.
Trial: NCT02954978
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 patients in group 1 will receive Placebo (sugar pill) one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up.
Trial: NCT02977286
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Oral Tablet po (enteral) twice daily
Trial: NCT02977286
Drug: Senna 217 Mg Oral Tablet
RxNorm normalized name: senna 217 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Senna 127 mg oral tablet daily if no spontaneous bowel movement \>/=3 days after scheduled opioid initiation; increase to two senna 127 mg tables if no no spontaneous bowel movement \>/=4 days after scheduled opioid initiation. Repeat two senna 127 mg tablets if no spontaneous bowel movement \>/=5 days after scheduled opioid initiation. Repeat two senna 127 mg tablets if no spontaneous bowel movement \>/=6 days after scheduled opioid initiation.
Trial: NCT00727740
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin 100 mg liquid suspension (25 mg/5 ml) which is 20 cc of suspension is instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. Following instillation of the suspension, the catheter is flushed with 5 cc of normal saline.
Trial: NCT00727740
Drug: Placebo suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo suspension which is made by the Investigational Drug Service (IDS) by adding the appropriate dye coloring to normal saline so that the appearance is identical to the indomethacin suspension. The placebo solution is also instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. Following instillation of the placebo suspension, the catheter is flushed with 5 cc of normal saline.
Trial: NCT04153929
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for Injection
Trial: NCT00753623
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In a crossover design, a subject will be first assigned to the ramelteon or placebo arm and then switched over to the opposite arm.
Trial: NCT02292472
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inject intramuscularly once in visit 2
Trial: NCT00607581
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cyclophosphamide: 500 mg orally on days 1, 8, 15
Trial: NCT01465763
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plabebo oral BID
Trial: NCT00770900
Drug: Comparator: placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asthmatic children and teenagers took Placebo tablet daily for 12 weeks.
Trial: NCT04532567
Drug: GLPG1205
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG1205 film-coated tablets
Trial: NCT04532567
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo film-coated tablets
Trial: NCT01030432
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 0 mg, twice daily, 48 weeks
Trial: NCT01030432
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 0 mg, twice daily, 0 or 12 weeks (depending on response) beginning at Week 12
Trial: NCT01030432
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 0 mg, twice daily 24 weeks
Trial: NCT00002489
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002489
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002489
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002489
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02903017
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Via nasogastric tube, 100 mL
Trial: NCT03197766
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of 15 μg/kg of placebo daily
Trial: NCT03534895
Drug: Postoperative analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV acetaminophen 1g + IV ketorolac 30mg
Trial: NCT03534895
Drug: Rescue analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 2mg/Kg IV in 100mL of normal saline, if pain NRS\>3.
Trial: NCT03534895
Drug: Wound infiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wound infiltration with 10mL of ropivacaine 0.75%, in open inguinal hernia repair
Trial: NCT03534895
Drug: Analgesia at home
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral acetaminophen 1g 6/6h + ibuprofen 400mg 8/8h (+ rescue analgesia with tramadol 50mg 6/6h)
Trial: NCT02987244
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide(750mg/m2) was administered intravenously on d1
Trial: NCT02758743
Drug: Acetium Lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release L-Cysteine to block smoke.derived acetaldehyde in saliva thereby inhibiting the formation of harmans
Trial: NCT02758743
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with no active substance will not have the effect on intervention device.
Trial: NCT04678531
Drug: Baby shampoo
RxNorm normalized name: BABY SHAMPOO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baby shampoo will be used in 23 patients for 8 weeks and will be discontinued in the following 4 weeks.
Trial: NCT00380315
Drug: AG1321001(drug)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02388347
Drug: Placebo SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single-dose of Placebo subcutaneous (SC) injection on Day 1.
Trial: NCT03662269
Drug: indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: indomethacin (75mg, bid, po, 14days)
Trial: NCT03662269
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (75mg, bid, po, 14days)
Trial: NCT01799720
Drug: Hypercholesterolemic diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Finally 52 women between 25 and 75 years old randomly were distributed into three groups. Participants from group 3 only received the diet and no capsules. Follow-up 30 days
Trial: NCT00349466
Drug: CF101
RxNorm normalized name: CF101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally CF101 1mg
Trial: NCT00349466
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally matching Placebo
Trial: NCT00487825
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo was supplied in form of a lyophilized cake (Powder for Solution for Infusion). At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
Trial: NCT00487825
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) was supplied in tablet form, each of 2.5 mg strength.
Trial: NCT02358668
Drug: BTI320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.
Trial: NCT02358668
Drug: BTI320 matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03153150
Drug: Acenocoumarol
RxNorm normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
Trial: NCT02904109
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral administration of placebo mannitol for 8 days.
Trial: NCT01443403
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets administered orally once a day.
Trial: NCT00390260
Drug: MK0966 / Duration of Treatment: 1 Days
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00390260
Drug: Comparator: acetaminophen (+) hydrocodone bitartrate / Duration of Treatment: 1 Days
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00390260
Drug: Comparator: placebo (unspecified) / Duration of Treatment: 1 Days
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03489005
Drug: BIA 5-1058
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive BIA 5-1058 tablets (containing 100 mg) as single, oral doses 30 minutes after the start of a moderate mealas follows:~* 400 mg BIA 5 1058, as 4 × 100 mg tablets and 8 placebo tablets~* 1200 mg BIA 5 1058, as 12 × 100 mg tablets
Trial: NCT01621243
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be dosed daily
Trial: NCT03489005
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets administered as follows:~- placebo, as 12 × 0-mg tablets
Trial: NCT01953445
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no